Prostate News and Research

RSS

CyberKnife Robotic Radiosurgery System brings new hope to patients with inoperable tumors

The CyberKnife Institute at Mercy Hospital, Miami’s first hospital-based CyberKnife® Robotic Radiosurgery System, will bring new hope to patients with inoperable or surgically complex tumors when it opens its doors January of 2010.

22 Dec 2009

Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy

Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today that they have entered into a global license and collaboration agreement to develop and commercialize OGX-011, as well as an agreement to purchase shares in OncoGenex. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance.

21 Dec 2009

OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries

Isis Pharmaceuticals, Inc. today announced that it will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. as a result of OncoGenex' license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a second-generation antisense drug co-discovered by Isis and OncoGenex that has completed a successful Phase 2 program in patients with advanced prostate cancer and advanced non-small cell lung cancer.

21 Dec 2009

VA apologizes for faulty prostate-cancer program in Pa. but denies radiation violations

"The Department of Veterans Affairs yesterday apologized repeatedly for a prostate-cancer program that gave incorrect radiation doses to veterans for six years at its main Philadelphia hospital," The Philadelphia Inquirer reports.

18 Dec 2009

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

18 Dec 2009

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the termination of its agreement with sanofi-aventis U.S. ( SNY) dated March 5, 2009 for the development, commercialization and licensing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market, following the Company's announcement last week of the results for its European Phase 3 study for cetrorelix in BPH.

18 Dec 2009

Advanced Medical Diagnostics SA to open 15 Tissue Differentiation Diagnostic Centres

Advanced Medical Diagnostics SA, a privately held company committed to providing innovative computer-aided solutions (HistoScanning™) that improve the diagnostic interpretation of ultrasound scans, today announced a collaboration with the BUND-DER-UROLOGEN for the opening of 15 Tissue Differentiation Diagnostic Centres.

18 Dec 2009

FDA advisory committee votes against approval of Tarceva for lung cancer treatment

Yesterday, an advisory committee to the Food and Drug Administration voted against the approval of Tarceva(R) (erlotinib) as maintenance treatment for advanced lung cancer patients.

18 Dec 2009

Study findings highlight the need to develop specific health policies to address social disparities

Racial and ethnic disparities in cancer survival are greatest for cancers that can be detected early and treated successfully, including breast and prostate cancer, according to a study by researchers at Columbia University's Mailman School of Public Health and Herbert Irving Comprehensive Cancer Center (HICCC) at Columbia University Medical Center/NewYork-Presbyterian Hospital.

18 Dec 2009

Brachytherapy for lung cancer

A 58-year-old man who lives in Corona, Queens came to the emergency room of New York Hospital Queens (NYHQ) with extreme pain and tingling in his left arm. Although he did not realize it at the time, he had lung cancer. Recently, he made medical history as the first patient in the United States to be treated for lung cancer through the use of radioactive pellets placed directly in the tumor, and today his recovery is going well. Known as brachytherapy, this treatment approach is commonly used to treat prostate cancer.

18 Dec 2009

$15 million federal funds for new cancer research program

As a result of C3: Colorectal Cancer Coalition's advocacy efforts, $15 million for a new peer reviewed cancer research program is included in the final Fiscal Year 2010 Defense Appropriations Bill.

17 Dec 2009

Phase Forward’s InForm Global Trial Management solution standardized to support early-stage clinical trials

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced that Cancer Research UK’s Drug Development Office – the drug development arm of the world’s largest independent organization dedicated to cancer research – is standardizing on Phase Forward’s InForm™ Global Trial Management solution to support its diverse portfolio of early-stage clinical trials.

17 Dec 2009

Prostate cancer tests promised but not delivered

Men's Health Network calls on Congress to ensure that healthcare reform does not override the prostate cancer testing benefit currently required of insurance companies in 37 states.

16 Dec 2009

Discovery may yield new treatments for hormone-resistant prostate cancer

Patients with advanced prostate cancer are often treated with hormones, but when the tumours start growing again they have more and different blood vessels, reveals a thesis from the Sahlgrenska Academy, at the University of Gothenburg, Sweden. This discovery paves the way for new treatments for hormone-resistant prostate cancer.

16 Dec 2009

Preventing tumours from making new blood vessels can also prevent spread of cancer

15 Dec 2009

Health experts discuss new treatment strategies for lung cancer at AACR-IASLC Joint Conference

In partnership with the International Association for the Study of Lung Cancer, the American Association for Cancer Research will host the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, which will bring together leaders from all over the world who share the goal of eradicating this form of cancer.

15 Dec 2009

New program to help maintain bone health in men with prostate cancer on ADT announced

Watson Pharmaceuticals, Inc. today announced a new program encouraging health professionals to help maintain the bone health of prostate cancer patients who are on long-term androgen deprivation therapy (ADT).

15 Dec 2009

Varian Medical Systems introduces RapidArc radiotherapy technology in Finland

Cancer patients in Finland have gained access to more advanced treatments with the introduction of RapidArc® radiotherapy technology from Varian Medical Systems at the only private radiotherapy clinic in the Nordic region.

15 Dec 2009

Researchers present new data for diagnosis and management of beast cancer

As therapies for breast cancer continue to emerge, the issues of how to best monitor success and gauge prognosis remain important questions.

14 Dec 2009

Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin

Algeta ASA, the cancer therapeutics company, announces that the first clinical center in the US, the Tulane Cancer Center, New Orleans, has started randomizing patients in the phase III clinical study of Alpharadin in men with castration-resistant (also known as hormone-refractory) prostate cancer (CRPC) that has metastasized to the skeleton.

14 Dec 2009

Prostate News and Research

CyberKnife Robotic Radiosurgery System brings new hope to patients with inoperable tumors

Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy

OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries

VA apologizes for faulty prostate-cancer program in Pa. but denies radiation violations

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

Advanced Medical Diagnostics SA to open 15 Tissue Differentiation Diagnostic Centres

FDA advisory committee votes against approval of Tarceva for lung cancer treatment

Study findings highlight the need to develop specific health policies to address social disparities

Brachytherapy for lung cancer

$15 million federal funds for new cancer research program

Phase Forward’s InForm Global Trial Management solution standardized to support early-stage clinical trials

Prostate cancer tests promised but not delivered

Discovery may yield new treatments for hormone-resistant prostate cancer

Preventing tumours from making new blood vessels can also prevent spread of cancer

Health experts discuss new treatment strategies for lung cancer at AACR-IASLC Joint Conference

New program to help maintain bone health in men with prostate cancer on ADT announced

Varian Medical Systems introduces RapidArc radiotherapy technology in Finland

Researchers present new data for diagnosis and management of beast cancer

Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News